Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL
Clinical trial NCT07457177 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07457177
- Sponsor
- LIANG WANG
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-10
- Primary completion
- 2028-01-30
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.